Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
用于失眠症,特别适用于治疗难以入睡型失眠症。
The Lindner Center of HOPE, Mason, Ohio, United States
Lehigh Valley Hospital, Department of Psychiatry, Allentown, Pennsylvania, United States
Shriners Hospital for Children, Cincinnati, Ohio, United States
VA Palo Alto Health Care System, Palo Alto, California, United States
Lehigh Valley Hospital, Department of Psychiatry, Allentown, Pennsylvania, United States
VA Long Beach Healthcare System, Long Beach, California, United States
Patricia Shipley, MD, Charlottesville, Virginia, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.